OncoPharm

A case study in misbranding promotional materials and how to help FDA regulate them.

Foundations of OncoPharm: capecitabine

A foundational topic in oncology - managing toxicities of tamoxifen and AI's in breast cancer patients. An excellent evidence-based review was recently published, and is worth our time on the Pod.

Link: https://doi.org/10.1016/S1470-2045(20)30666-5

So-called negative trials still offer information. We discuss ECOG-ACRIN EA1131 in breast cancer and TOURMALINE-MM1 in myeloma in this epidose.

EA1131: https://ascopubs.org/doi/pdf/10.1200/JCO.21.00976

TOURMALINE-MM1 (final OS analysis): https://ascopubs.org/doi/pdf/10.1200/JCO.21.00972

Why is learning oncology so hard? To get the students perspective I ask a few pharmacy students why in hopes of learning how to better teach and precept oncology trainees.

Highlighting results presented at ASCO's 2021 annual meeting.

Two new drugs approved in the last week:

1. sotorasib, a drug for a specific KRAS mutation (G12C) in 2nd line metastatic NSCLC

2. infigratinib, basically a "me too" FGFR inhibitor approved for metastatic cholangiocarcinoma

We all discuss the latest adjuvant CHECKMATE study (nivolumab in urothelial carcinoma) and a recent study of seropositivity in cancer patients following COVID vaccination.

Discussing a first of its kind drug, amivantamab, a bispecific (MET & EGFR) monoclonal antibody just approved for advanced exon20 insertion NSCLC (2nd line).

The Foundations of Oncopharm series tackles veneotoclax with special guest, Dr. Kayleigh Marx - clinical pharmacy specialist in leukemia. She tells us everything we need to know and consider when using venetoclax for leukemia patients.

Drug-drug interaction references:

1. https://doi.org/10.1002/jcph.858

2. https://doi.org/10.1016/j.clinthera.2017.01.003

3. https://doi.org/10.1002/jcph.730

4. https://doi.org/10.1007/s12325-018-0793-y

ASCO releases updated guidelines for the dosing of cancer drugs in patients with obesity. Not a ton new from the original guidelines, but worthy of discussion.

Link: https://ascopubs.org/doi/full/10.1200/JCO.21.00471